🔴 Gilead Sciences is trading 4.38% down in after-hours trading with no credible company-specific explanation

Gilead Sciences is trading 4.38% down at $139.30 after falling from the August 28 regular-session close of $145.68, with no credible company-specific announcement found to explain the after-hours decline.

• The FDA’s August 27 approval of Bixlenvo was favorable news, not a clear bearish catalyst.
• Broader market performance was mixed: the S&P 500 fell 0.21%, while the Nasdaq Composite rose 0.98%, providing limited explanation.